See also: Clinical Trial
NCT00256750 is belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial. Other study IDs include: IM103-008, BENEFIT.
|Purpose||Patients||Patients with evaluations||Perceived Effectiveness|
|Transplant rejection prevention||2||1|
- Can't tell
|500 mg monthly||1|
|750 mg monthly||1|
|500 mg every other week||1|